Lenacapavir (GS-6207) is the first HIV-1 capsid inhibitor approved by the U.S. Food and Drug Administration, the European Medicines Agency, and Health Canada for the treatment of MDR HIV-1 infection.[3]
Molecular Weight:
968.28
Purity:
99.25%
CAS Number:
[2189684-44-2]
Formula:
C39H32ClF10N7O5S2
Target:
HIV Protease
T11465
* VAT and and shipping costs not included. Errors and price changes excepted
